Binding molecules to the human OX40 receptor
The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
1. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a heavy chain or an antigen-binding fragment thereof, and a light chain or an antigen-binding fragment thereof of an antibody that specifically binds OX40R, wherein said antibody comprises:
(a) a heavy chain variable region (V H ) comprising:
a V H CDR1 region comprising an amino acid sequence of SEQ ID NO: 13,
a V H CDR2 region comprising an amino acid sequence of SEQ ID NO: 14, and
a V H CDR3 region comprising an amino acid sequence of SEQ ID NO: 15; and a light chain variable region (V L ) comprising:
a V L CDR1 region comprising an amino acid sequence of SEQ ID NO: 16,
a V L CDR2 region comprising an amino acid sequence of SEQ ID NO: 17, and
a V L CDR3 region comprising an amino acid sequence of SEQ ID NO: 18;
(b) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 19; and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 20; or
(c) a heavy chain comprising an amino acid sequence of SEQ ID NO: 21; and a light chain comprising an amino acid sequence of SEQ ID NO: 22.
2. A vector comprising the isolated nucleic acid molecule according to claim 1 .
3. The vector according to claim 2 , further comprising an expression control sequence operably linked to said isolated nucleic acid molecule.
4. The vector according to claim 2 , wherein said vector is selected from the group consisting of a plasmid expression vector, a retrovirus expression vector, an adenovirus expression vector, and an adeno-associated virus expression vector.
5. A host cell comprising said vector according to claim 2 .
6. The host cell according to claim 5 , wherein said host cell is selected from the group consisting of a mammalian cell, an insect cell, a plant cell, a bacterial cell, and a yeast cell.
7. A method for producing a monoclonal antibody or an antigen-binding fragment thereof that specifically binds human OX40R, comprising culturing said host cell according to claim 5 under suitable conditions and recovering said monoclonal antibody or said antigen-binding fragment.
8. An isolated nucleic acid molecule comprising:
(a) a nucleic acid sequence of SEQ ID NO: 23;
(b) a nucleic acid sequence of SEQ ID NO: 24; or
(c) a nucleic acid sequence of (a) and a nucleic acid sequence of (b).
9. A vector comprising the isolated nucleic acid molecule according to claim 8 .
10. The vector according to claim 9 , further comprising an expression control sequence operably linked to said isolated nucleic acid molecule.
11. The vector according to claim 9 , wherein said vector is selected from the group consisting of a plasmid expression vector, a retrovirus expression vector, an adenovirus expression vector, and an adeno-associated virus expression vector.
12. A host cell comprising said vector according to claim 9 .
13. The host cell according to claim 12 , wherein said host cell is selected from the group consisting of a mammalian cell, an insect cell, a plant cell, a bacterial cell, and a yeast cell.
14. A method for producing a monoclonal antibody or an antigen-binding fragment thereof that specifically binds human OX40R, comprising culturing said host cell according to claim 12 under suitable conditions and recovering said monoclonal antibody or said antigen-binding fragment.
15. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the amino acid sequences of SEQ ID NOs: 13, 14, and 15.
16. The isolated nucleic acid molecule according to claim 15 , wherein said nucleic acid sequence further encodes the amino acid sequences of SEQ ID NOs: 16, 17, and 18.